Grünenthal appoints Gabriel Baertschi as Chairman and Chief Executive


He follows Prof. Dr Eric-Paul Paques who retires after 23 years with the company

Gabriel Baertschi

Gabriel Baertschi

German pharmaceutical firm Grünenthal Group has named Gabriel Baertschi to become CEO as of 1 October.

Baertschi will join Grünenthal from AstraZeneca, where he is currently country president for Japan. He succeeds Prof. Dr Eric-Paul Pâques.

Baertschi has more than 17 years of international experience in the pharmaceutical industry. Prior to his current role at AstraZeneca, he was country president for Germany and earlier in his career was country manager in various emerging markets.

Sign up for your free email newsletter

During the last quarter of 2016, both Pâques and Baertschi will work together to ensure a smooth transition. Under Pâques' leadership, Grünenthal has significantly expanded its global business, especially in Latin America, Europe as well as the US by bringing new innovative treatments to market, and sharpened its strategy with regards to R&D and partnering and growing new promising business areas such as the hospital business.